Vitamin-C-megaskorbicka-liecba.pdf - Zdravie.sk

Vitamín C a megaskorbická liečba – zabudnutý poklad 373 / 436
Zdroje
[514] Mashour S, Turner JF Jr, Merrell R. Acute renal failure, oxalosis, and vitamin C supplementation: a case
report and review of the literature. Chest. 2000 Aug;118(2):561-3. PMID:10936161.
DOI:10.1378/chest.118.2.561. http://www.chestjournal.org/content/118/2/561.full
[515] Gabardi S, Munz K, Ulbricht C. A Review of Dietary Supplement-Induced Renal Dysfunction. Clin J Am Soc
Nephrol. 2007 Jul;2(4):757-65. Epub 2007 May 30. PMID:17699493.
http://cjasn.asnjournals.org/cgi/content/full/2/4/757
[516] Alkhunaizi, AM, Chan, L Secondary oxalosis: a cause of delayed recovery of renal function in the setting of
acute renal failure. J Am Soc Nephrol. 1996 Nov;7(11):2320-6. PMID:8959621.
http://jasn.asnjournals.org/cgi/reprint/7/11/2320
[517] Auer BL, Auer D, Rodgers AL. Relative hyperoxaluria, crystalluria and haematuria after megadose ingestion
of vitamin C. Eur J Clin Invest. 1998 Sep;28(9):695-700. PMID:9767367. DOI:10.1046/j.1365-
2362.1998.00349.x.
[518] Rivers JM. Safety of high-Ievel vitamin C ingestion. In: Third Conference on AA. Ann NY_Acad Sci.
1987;498:95-102. Možno ide o toto: PMID:3304071.
[519] Massey, L. Safety of vitamin C. Am J Clin Nutr. 2005 Aug;82(2):488; author reply 489. PMID:16088001.
http://www.ajcn.org/cgi/content/full/82/2/488
[520] Chai W, Liebman M, Kynast-Gales S, Massey L. Oxalate absorption and endogenous oxalate synthesis from
ascorbate in calcium oxalate stone formers and non-stone formers. Am J Kidney Dis. 2004 Dec;44(6):1060-9.
PMID:15558527. DOI:10.1053/j.ajkd.2004.08.028.
[521] Lapčík O. Komu hrozí kurděje. Vesmír 2001/9;80:497. ISSN 1214-4029.
http://www.vesmir.cz/clanky/clanek/id/4715
[522] Schwille PO, Schmiedl A, Herrmann U, Manoharan M, Fan J, Sharma V, Gottlieb D. Ascorbic acid in
idiopathic recurrent calcium urolithiasis in humans--does it have an abettor role in oxalate, and calcium
oxalate crystallization? Urol Res. 2000 Jun;28(3):167-77. PMID:10929425.
[523] Tiselius HG, Almgård LE. The diurnal urinary excretion of oxalate and the effect of pyridoxine and ascorbate
on oxalate excretion. Eur Urol. 1977;3(1):41-6. PMID:556987.
[524] Yamazaki K, Mitsuhashi T, Yamada E, Yamada T, Kosaka S, Takano K, Obara T, Sato K. Amiodarone
reversibly decreases sodium-iodide symporter mRNA expression at therapeutic concentrations and induces
antioxidant responses at supraphysiological concentrations in cultured human thyroid follicles. Thyroid. 2007
Dec;17(12):1189-200. PMID:18020914. DOI:10.1089/thy.2007.0215.
[525] Markou K, Georgopoulos N, Kyriazopoulou V, Vagenakis AG. Iodine-Induced hypothyroidism. Thyroid. 2001
May;11(5):501-10. PMID:11396709. DOI:10.1089/105072501300176462.
[526] Urivetzky M, Kessaris D, Smith AD. Ascorbic acid overdosing: a risk factor for calcium oxalate
nephrolithiasis. J Urol. 1992 May;147(5):1215-8. PMID:1569652.
[527] Pearce EN, Gerber AR, Gootnick DB, Khan LK, Li R, Pino S, Braverman LE. Effects of chronic iodine excess
in a cohort of long-term American workers in West Africa. J Clin Endocrinol Metab. 2002 Dec;87(12):5499-502.
PMID:12466344. http://jcem.endojournals.org/cgi/content/full/87/12/5499
[528] Heckers H, Wagner I, Schmelz E & Trenkel A. Zur diatetischen Therapie und Pravention von Calcium-
Oxalat-Nierensteinen. Ernahrungs-umschau. 1993; 40: 416–20.
[529] Atkins GL, Dean BM, Griffin WJ, Scowen EF, Watts RWE. Primary hyperoxaluria. The relation between
ascorbic acid and the increased urinary excretion of oxalate. Lancet 1963 Nov 23;2(7317):1096-7.
PMID:14063425.
[530] Eng PH, Cardona GR, Fang SL, Previti M, Alex S, Carrasco N, Chin WW, Braverman LE. Escape from the
acute Wolff-Chaikoff effect is associated with a decrease in thyroid sodium/iodide symporter messenger
ribonucleic acid and protein. Endocrinology. 1999 Aug;140(8):3404-10. PMID:10433193.
http://endo.endojournals.org/cgi/reprint/140/8/3404
[531] Wikipedia. Flavonoid. http://en.wikipedia.org/wiki/Flavonoid
[532] Mitch WE, Johnson MW, Kirshenbaum JM, Lopez RE. Effect of large oral doses of ascorbic acid on uric acid
excretion by normal subjects. Clin Pharmacol Ther. 1981 Mar;29(3):318-21. PMID:7471601.
[533] Fituri N, Allawi N, Bentley M, Costello J. Urinary and plasma oxalate during ingestion of pure ascorbic acid:
a re-evaluation. Eur Urol. 1983;9(5):312-5. PMID:6628476.
[534] Su SB, Silver PB, Zhang M, Chan CC, Caspi RR. Pertussis toxin inhibits induction of tissue-specific
autoimmune disease by disrupting G protein-coupled signals. J Immunol. 2001 Jul 1;167(1):250-6.
PMID:11418656. http://www.jimmunol.org/cgi/content/full/167/1/250
[535] Seltzer MA, Low RK, McDonald M, Shami GS, Stoller ML. Dietary manipulation with lemonade to treat
hypocitraturic calcium nephrolithiasis. J Urol. 1996 Sep;156(3):907-9. PMID:8709360. PII: S0022-
5347(01)65659-3.
[536] Pak CY. Citrate and renal calculi: an update. Miner Electrolyte Metab. 1994;20(6):371-7. PMID:7783699.
[537] Curhan GC, Willett WC, Speizer FE, Stampfer MJ. Beverage use and risk for kidney stones in women. Ann
Intern Med. 1998 Apr 1;128(7):534-40. PMID:9518397. http://www.annals.org/content/128/7/534.long
[538] Sidhu H, Schmidt ME & Cornelius JG et al. Direct correlation between hyperoxaluria/oxalate stone disease
and the absence of the gastrointestinal tract-dwelling bacterium Oxalobacter formigenes: Possible prevention
by gut recolonization or enzyme replacement therapy. J Am Soc Nephr. 1999; 10 Suppl 1:334–40.
[539] Rattan V, Sidhu H, Vaidyanathan S, Thind SK, Nath R. Effect of combined supplementation of magnesium
oxide and pyridoxine in calcium-oxalate stone formers. Urol Res. 1994;22(3):161-5. PMID:7992461.
DOI:10.1007/BF00571844.
[540] Prien El, Gershoff SF. Magnesium oxide-pyridoxine therapy for recurrent calcium oxalate calculi. J Urol.
1974 Oct;112(4):509-12. PMID:4414543.
[541] Dr. James Balch. Mitamins Essential Formula [MEF] for Kidney Stones. Mitamins Inc.
http://www.mitamins.com/disease/Kidney-Stones.html